Exploring Potential HER2-Positive Breast Cancer Treatments for the Future
Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.
Jasmeet C. Singh, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS).
Although the field has come a long with developing new treatment options for patients with breast cancers that overexpress HER2, Singh notes that there is still room for improvement. One possibility for the future is that novel agents will be used to develop promising combinations to further improve pathologic complete response (pCR) rates and overall response rates.
There have been exciting pCR data in triple-negative disease showing that the addition of immunotherapy improves pCRs. Singh says it may also be possible to study how surgery can be avoided in some patients with HER2-positive disease.
Learn more about the presentation from 2019 SABCS:https://www.targetedonc.com/conference/sabcs-2019
<< View more resources and information regarding breast cancer
Metronomic Capecitabine Continues Efficacy With Pyrotinib in HER2+ Advanced Breast Cancer
December 4th 2023Results from an international phase 2 study show that using metronomic capecitabine in combination with the tyrosine kinase inhibitor pyrotinib continued to have promising efficacy results for patients with HER2-positive metastatic breast cancer.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
November 22nd 2023In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.
Read More
